Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)
Safety and Efficacy Study of Eculizumab in Shiga-Toxin Producing Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)
This protocol is designed to collect safety and efficacy data on patients that have been or
 will be treated with eculizumab for STEC-HUS, in the context of the 2011 STEC-HUS epidemic in
 Germany.
Inclusion Criteria:

 1. Patient must be willing and able to give written informed consent/Assent.

 2. Adults, adolescents, or pediatric (≥2 months and ≥5kg) patients

 3. Patient has been diagnosed with Escherichia Coli Hemolytic-Uremic Syndrome (STEC-HUS)

 Exclusion Criteria:

 1. Known complement regulatory mutation or family history of complement regulatory
 mutation

 2. Unresolved systemic meningococcal disease

 3. 3. Hypersensitivity to eculizumab, to murine proteins or to one of the excipients